Literature DB >> 16406093

Microglial phenotype: is the commitment reversible?

Michal Schwartz1, Oleg Butovsky, Wolfgang Brück, Uwe-Karsten Hanisch.   

Abstract

Microglia, the standby cells for immune defense in the CNS, have a reputation for exacerbating the neural damage that occurs in neurodegenerative diseases. However, research over the past few years has established that microglia do not constitute a single, uniform cell population, but rather comprise a family of cells with diverse phenotypes--some that are beneficial and others that the CNS can barely tolerate and that are therefore destructive. This finding raised several questions. What instructs microglia to acquire a particular phenotype, and how do these phenotypes differ? How committed are microglia to a specific phenotype? Can destructive microglia become protective, and can protective microglia retain their beneficial phenotype even when they encounter a destructive environment? Here, we address these questions, and the background of research that elicited them.

Entities:  

Mesh:

Year:  2006        PMID: 16406093     DOI: 10.1016/j.tins.2005.12.005

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  154 in total

1.  CCL2 promotes P2X4 receptor trafficking to the cell surface of microglia.

Authors:  Emika Toyomitsu; Makoto Tsuda; Tomohiro Yamashita; Hidetoshi Tozaki-Saitoh; Yoshitaka Tanaka; Kazuhide Inoue
Journal:  Purinergic Signal       Date:  2012-01-06       Impact factor: 3.765

2.  The impact of glial activation in the aging brain.

Authors:  Aileen M Lynch; Kevin J Murphy; Brian F Deighan; Julie-Ann O'Reilly; Yuri K Gun'ko; Thelma R Cowley; Rodrigo E Gonzalez-Reyes; Marina A Lynch
Journal:  Aging Dis       Date:  2010-09-04       Impact factor: 6.745

3.  Overcoming endogenous constraints on neuronal regeneration.

Authors:  Nassir Mokarram; Ravi V Bellamkonda
Journal:  IEEE Trans Biomed Eng       Date:  2010-12-30       Impact factor: 4.538

4.  Real-time analysis of microglial activation and motility in hepatic and hyperammonemic encephalopathy.

Authors:  V Rangroo Thrane; A S Thrane; J Chang; J Chanag; V Alleluia; E A Nagelhus; M Nedergaard
Journal:  Neuroscience       Date:  2012-06-21       Impact factor: 3.590

Review 5.  Rett syndrome and other autism spectrum disorders--brain diseases of immune malfunction?

Authors:  N C Derecki; E Privman; J Kipnis
Journal:  Mol Psychiatry       Date:  2010-02-23       Impact factor: 15.992

Review 6.  Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Authors:  Richard S Jope; Christopher J Yuskaitis; Eléonore Beurel
Journal:  Neurochem Res       Date:  2006-08-30       Impact factor: 3.996

7.  Dual role of CD38 in microglial activation and activation-induced cell death.

Authors:  Lior Mayo; Jasmine Jacob-Hirsch; Ninette Amariglio; Gideon Rechavi; Marie-Jo Moutin; Frances E Lund; Reuven Stein
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

8.  Acute in vivo exposure to interferon-gamma enables resident brain dendritic cells to become effective antigen presenting cells.

Authors:  Andres Gottfried-Blackmore; Ulrike W Kaunzner; Juliana Idoyaga; Jennifer C Felger; Bruce S McEwen; Karen Bulloch
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-11       Impact factor: 11.205

9.  Modulation of morphological changes of microglia and neuroprotection by monocyte chemoattractant protein-1 in experimental glaucoma.

Authors:  Kin Chiu; Sze-Chun Yeung; Kwok-Fai So; Raymond Chuen-Chung Chang
Journal:  Cell Mol Immunol       Date:  2010-01       Impact factor: 11.530

Review 10.  The role of glutamate and the immune system in organophosphate-induced CNS damage.

Authors:  Arik Eisenkraft; Avshalom Falk; Arseny Finkelstein
Journal:  Neurotox Res       Date:  2013-03-27       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.